The University of Copenhagen is excited to announce Haut.AI as Tier 3 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.
Haut.AI is a technology company developing cutting-edge artificial intelligence and generative AI tools for skin health, personalized skincare, and clinical research. Founded by scientists and supported by a team of experts in AI, biology, biophysics, and dermatology, Haut.AI applies scientific rigor and technological depth to support every stage of the beauty product lifecycle, from R&D to user engagement and product discovery. Its ongoing work in generative AI, machine learning, and multi-modal analysis enables partners to create intelligent, adaptive experiences that extend beyond facial skin into hair analysis, conversational AI, and next-generation skin longevity focused tech. The company’s AI systems are trusted by over 100 organizations globally, including industry leaders such as Ulta Beauty, NAOS, Beiersdorf and Grupo Boticário.
Driven by scientific rigor, Haut.AI has contributed over 15 peer-reviewed publications and holds patented technologies in facial anonymization. Its tools are supporting the development of products grounded in a deep understanding of individual skin characteristics.
As part of its ongoing commitment to advancing aging science, Haut.AI will showcase its latest research at the 2025 Aging Research & Drug Discovery (ARDD) conference. On August 28 at 16:20, CEO and co-founder Anastasia Georgievskaya will present recent work exploring the use of generative AI, highlighting how this technology can support innovation and research across the longevity and skin health landscape.
The presentation will explore the company’s pioneering work in this space, specifically its award-winning technology, SkinGPT, a generative AI system designed to simulate the effects of skincare and aging on facial skin. By leveraging advanced diffusion models, the team examined how synthetic imagery can capture age-related changes, such as texture, pigmentation, and fine lines, across diverse populations.
By enabling the simulation of aging trajectories without relying on sensitive real-world datasets, the model supports scientific exploration of visual biomarkers in aging. It also equips brands and researchers with a new way to design, test, and personalize interventions grounded in deeper understanding of the skin’s biological evolution.
ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.
“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.
Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.
For further information, images or interviews, please contact:
ardd@pharma.ai
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.
About Haut.AI
Haut.AI is a SaaS technology company at the forefront of generative AI-powered skincare personalization. Founded by scientists and AI innovators, Haut.AI collaborates with leading beauty brands, including Beiersdorf, Ulta Beauty, and Grupo Boticário.
For more information, visit www.haut.ai